Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A

V. Bafunno, R. Santacroce, M. Chetta, F. Peyvandi, F. Sessa, E. Chinni, V. Longo, M. Margaglione

Research output: Contribution to journalArticle

Abstract

Development of inhibitory antibodies is perhaps the most serious complication of FVIII replacement therapy, precluding efficient clinical management of patients with haemophilia A (HA). The development and function of immune system are also regulated by microRNAs (miRNAs). Mutations and changes in the level of expression of some miRNA genes have been associated with the onset and progression of immunological disorders. The aim of this study was to investigate new genetic polymorphisms in loci for miRNA and their targets to evaluate whether these SNPs may confer susceptibility to inhibitor development in patients with HA. Italian HA patients with and without inhibitors and healthy controls were recruited in this study. For SNP analysis, standard DNA sequencing method was used. We have studied four SNPs, i.e. rs36101366, rs34683807, rs1803603 and rs3024496 located in the 3′UTR of F8 and IL-10 genes. These SNPs have been checked for their frequencies in patients with and without inhibitors, but no statistically significant differences were found. Then, we have searched for other genetic variants in loci for haematopoietic-specific miRNAs, i.e. hsa-mir-150, hsa-mir-155, hsa-mir-146a, hsa-mir-142, hsa-mir-181a and in a specific miRNA, hsa-mir-1184, i.e. predicted to be located in the intron 22 of F8 gene. For all miRNAs selected, we did not identify any sequence variation in our study population. This is the first study to demonstrate that there was no association between selected SNPs in miRNAs and their targets and the susceptibility to inhibitor development in people affected by HA.

Original languageEnglish
Pages (from-to)1003-1007
Number of pages5
JournalHaemophilia
Volume18
Issue number6
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Hemophilia A
MicroRNAs
Single Nucleotide Polymorphism
Genes
Genetic Polymorphisms
DNA Sequence Analysis
Interleukin-10
Introns
Immune System
Mutation
Antibodies
Population

Keywords

  • Autoimmune disease
  • Haemophilia A
  • Inhibitors
  • MiRNA
  • Polymorphisms
  • Susceptibility

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

Bafunno, V., Santacroce, R., Chetta, M., Peyvandi, F., Sessa, F., Chinni, E., ... Margaglione, M. (2012). Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. Haemophilia, 18(6), 1003-1007. https://doi.org/10.1111/j.1365-2516.2012.02882.x

Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. / Bafunno, V.; Santacroce, R.; Chetta, M.; Peyvandi, F.; Sessa, F.; Chinni, E.; Longo, V.; Margaglione, M.

In: Haemophilia, Vol. 18, No. 6, 11.2012, p. 1003-1007.

Research output: Contribution to journalArticle

Bafunno, V, Santacroce, R, Chetta, M, Peyvandi, F, Sessa, F, Chinni, E, Longo, V & Margaglione, M 2012, 'Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A', Haemophilia, vol. 18, no. 6, pp. 1003-1007. https://doi.org/10.1111/j.1365-2516.2012.02882.x
Bafunno, V. ; Santacroce, R. ; Chetta, M. ; Peyvandi, F. ; Sessa, F. ; Chinni, E. ; Longo, V. ; Margaglione, M. / Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. In: Haemophilia. 2012 ; Vol. 18, No. 6. pp. 1003-1007.
@article{b4666ffd51694abc8cd0ea7f05bde7ba,
title = "Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A",
abstract = "Development of inhibitory antibodies is perhaps the most serious complication of FVIII replacement therapy, precluding efficient clinical management of patients with haemophilia A (HA). The development and function of immune system are also regulated by microRNAs (miRNAs). Mutations and changes in the level of expression of some miRNA genes have been associated with the onset and progression of immunological disorders. The aim of this study was to investigate new genetic polymorphisms in loci for miRNA and their targets to evaluate whether these SNPs may confer susceptibility to inhibitor development in patients with HA. Italian HA patients with and without inhibitors and healthy controls were recruited in this study. For SNP analysis, standard DNA sequencing method was used. We have studied four SNPs, i.e. rs36101366, rs34683807, rs1803603 and rs3024496 located in the 3′UTR of F8 and IL-10 genes. These SNPs have been checked for their frequencies in patients with and without inhibitors, but no statistically significant differences were found. Then, we have searched for other genetic variants in loci for haematopoietic-specific miRNAs, i.e. hsa-mir-150, hsa-mir-155, hsa-mir-146a, hsa-mir-142, hsa-mir-181a and in a specific miRNA, hsa-mir-1184, i.e. predicted to be located in the intron 22 of F8 gene. For all miRNAs selected, we did not identify any sequence variation in our study population. This is the first study to demonstrate that there was no association between selected SNPs in miRNAs and their targets and the susceptibility to inhibitor development in people affected by HA.",
keywords = "Autoimmune disease, Haemophilia A, Inhibitors, MiRNA, Polymorphisms, Susceptibility",
author = "V. Bafunno and R. Santacroce and M. Chetta and F. Peyvandi and F. Sessa and E. Chinni and V. Longo and M. Margaglione",
year = "2012",
month = "11",
doi = "10.1111/j.1365-2516.2012.02882.x",
language = "English",
volume = "18",
pages = "1003--1007",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A

AU - Bafunno, V.

AU - Santacroce, R.

AU - Chetta, M.

AU - Peyvandi, F.

AU - Sessa, F.

AU - Chinni, E.

AU - Longo, V.

AU - Margaglione, M.

PY - 2012/11

Y1 - 2012/11

N2 - Development of inhibitory antibodies is perhaps the most serious complication of FVIII replacement therapy, precluding efficient clinical management of patients with haemophilia A (HA). The development and function of immune system are also regulated by microRNAs (miRNAs). Mutations and changes in the level of expression of some miRNA genes have been associated with the onset and progression of immunological disorders. The aim of this study was to investigate new genetic polymorphisms in loci for miRNA and their targets to evaluate whether these SNPs may confer susceptibility to inhibitor development in patients with HA. Italian HA patients with and without inhibitors and healthy controls were recruited in this study. For SNP analysis, standard DNA sequencing method was used. We have studied four SNPs, i.e. rs36101366, rs34683807, rs1803603 and rs3024496 located in the 3′UTR of F8 and IL-10 genes. These SNPs have been checked for their frequencies in patients with and without inhibitors, but no statistically significant differences were found. Then, we have searched for other genetic variants in loci for haematopoietic-specific miRNAs, i.e. hsa-mir-150, hsa-mir-155, hsa-mir-146a, hsa-mir-142, hsa-mir-181a and in a specific miRNA, hsa-mir-1184, i.e. predicted to be located in the intron 22 of F8 gene. For all miRNAs selected, we did not identify any sequence variation in our study population. This is the first study to demonstrate that there was no association between selected SNPs in miRNAs and their targets and the susceptibility to inhibitor development in people affected by HA.

AB - Development of inhibitory antibodies is perhaps the most serious complication of FVIII replacement therapy, precluding efficient clinical management of patients with haemophilia A (HA). The development and function of immune system are also regulated by microRNAs (miRNAs). Mutations and changes in the level of expression of some miRNA genes have been associated with the onset and progression of immunological disorders. The aim of this study was to investigate new genetic polymorphisms in loci for miRNA and their targets to evaluate whether these SNPs may confer susceptibility to inhibitor development in patients with HA. Italian HA patients with and without inhibitors and healthy controls were recruited in this study. For SNP analysis, standard DNA sequencing method was used. We have studied four SNPs, i.e. rs36101366, rs34683807, rs1803603 and rs3024496 located in the 3′UTR of F8 and IL-10 genes. These SNPs have been checked for their frequencies in patients with and without inhibitors, but no statistically significant differences were found. Then, we have searched for other genetic variants in loci for haematopoietic-specific miRNAs, i.e. hsa-mir-150, hsa-mir-155, hsa-mir-146a, hsa-mir-142, hsa-mir-181a and in a specific miRNA, hsa-mir-1184, i.e. predicted to be located in the intron 22 of F8 gene. For all miRNAs selected, we did not identify any sequence variation in our study population. This is the first study to demonstrate that there was no association between selected SNPs in miRNAs and their targets and the susceptibility to inhibitor development in people affected by HA.

KW - Autoimmune disease

KW - Haemophilia A

KW - Inhibitors

KW - MiRNA

KW - Polymorphisms

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=84868211753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868211753&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2012.02882.x

DO - 10.1111/j.1365-2516.2012.02882.x

M3 - Article

C2 - 22672258

AN - SCOPUS:84868211753

VL - 18

SP - 1003

EP - 1007

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -